Phase II study of tauromustine in disseminated malignant melanoma
Forty-seven patients with metastatic malignant melanoma took part in a phase II trial of tauromustine (TCNU), a new chlorethylnitrosourea based on the endogenous amino acid taurine. TCNU was given orally at a dosage of 130 mg/m 2 every fifth week. No patient had previously received cytotoxic therapy...
Gespeichert in:
| Veröffentlicht in: | European journal of cancer & clinical oncology 1989-04, Vol.25 (4), p.655-657 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 657 |
|---|---|
| container_issue | 4 |
| container_start_page | 655 |
| container_title | European journal of cancer & clinical oncology |
| container_volume | 25 |
| creator | Nolte, Hendrik Gjedde, Susanne B. Lindegaard-Madsen, Ebbe Bergh, Jonas Blomquist, Erik Mouridsen, Henning T. |
| description | Forty-seven patients with metastatic malignant melanoma took part in a phase II trial of tauromustine (TCNU), a new chlorethylnitrosourea based on the endogenous amino acid taurine. TCNU was given orally at a dosage of
130 mg/m
2
every fifth week. No patient had previously received cytotoxic therapy. Among
37 evaluable patients,
26 patients experienced progressive disease including seven patients with early death, five showed no change, and six partial responses, yielding an objective response rate of
16%. Responses were limited to subcutaneous, lymph node, bone and lung metastases. Median time to progression was
26 weeks for responders. The treatment schedule was well tolerated with a median dose of
88% of the predicted dose given during all cycles. Dose-limiting toxicity was thrombocytopenia. It appears that TCNU is active in disseminated malignant melanoma with a response rate similar to other nitrosoureas. |
| doi_str_mv | 10.1016/0277-5379(89)90201-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_15419014</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0277537989902010</els_id><sourcerecordid>15419014</sourcerecordid><originalsourceid>FETCH-LOGICAL-c417t-7f575e4e7b97c6e548d4426d75ddcafe4c848c1098ccfed362465b534400c8a93</originalsourceid><addsrcrecordid>eNp9kE9LxDAQxXNQ1nX1GyjkIKKHatImTXIRlsU_Cwt60HPIJlONNK0mrbDf3q5b9uhpYOa9x5sfQmeU3FBCy1uSC5HxQqgrqa4VyQnNyAGa7tdH6DilT0JyyXgxQZNcUFawfIrmLx8mAV4ucep6t8FthTvTxzb0qfMNYN9g51OC4BvTgcPB1P69MU2HA9SmaYM5QYeVqROcjnOG3h7uXxdP2er5cbmYrzLLqOgyUXHBgYFYK2FL4Ew6xvLSCe6cNRUwK5m0lChpbQWuKHNW8jUvGCPESqOKGbrc5X7F9ruH1Ongk4V6aAFtnzTljCoyvDVDbCe0sU0pQqW_og8mbjQlektLb7HoLRYtlf6jpclgOx_z-3UAtzeNqIb7xXg3yZq6iqaxPu1lgirKKB9kdzsZDCx-PESdrIfGgvMRbKdd6__v8Qs2X4dn</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>15419014</pqid></control><display><type>article</type><title>Phase II study of tauromustine in disseminated malignant melanoma</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Nolte, Hendrik ; Gjedde, Susanne B. ; Lindegaard-Madsen, Ebbe ; Bergh, Jonas ; Blomquist, Erik ; Mouridsen, Henning T.</creator><creatorcontrib>Nolte, Hendrik ; Gjedde, Susanne B. ; Lindegaard-Madsen, Ebbe ; Bergh, Jonas ; Blomquist, Erik ; Mouridsen, Henning T.</creatorcontrib><description>Forty-seven patients with metastatic malignant melanoma took part in a phase II trial of tauromustine (TCNU), a new chlorethylnitrosourea based on the endogenous amino acid taurine. TCNU was given orally at a dosage of
130 mg/m
2
every fifth week. No patient had previously received cytotoxic therapy. Among
37 evaluable patients,
26 patients experienced progressive disease including seven patients with early death, five showed no change, and six partial responses, yielding an objective response rate of
16%. Responses were limited to subcutaneous, lymph node, bone and lung metastases. Median time to progression was
26 weeks for responders. The treatment schedule was well tolerated with a median dose of
88% of the predicted dose given during all cycles. Dose-limiting toxicity was thrombocytopenia. It appears that TCNU is active in disseminated malignant melanoma with a response rate similar to other nitrosoureas.</description><identifier>ISSN: 0277-5379</identifier><identifier>DOI: 10.1016/0277-5379(89)90201-0</identifier><identifier>PMID: 2714342</identifier><identifier>CODEN: EJCODS</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Adolescent ; Adult ; Aged ; Antineoplastic agents ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Chemotherapy ; Drug Evaluation ; Humans ; Medical sciences ; Melanoma - drug therapy ; Melanoma - secondary ; Middle Aged ; Nitrosourea Compounds - adverse effects ; Nitrosourea Compounds - therapeutic use ; Pharmacology. Drug treatments ; Taurine - adverse effects ; Taurine - analogs & derivatives ; Taurine - therapeutic use</subject><ispartof>European journal of cancer & clinical oncology, 1989-04, Vol.25 (4), p.655-657</ispartof><rights>1989</rights><rights>1989 INIST-CNRS</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c417t-7f575e4e7b97c6e548d4426d75ddcafe4c848c1098ccfed362465b534400c8a93</citedby><cites>FETCH-LOGICAL-c417t-7f575e4e7b97c6e548d4426d75ddcafe4c848c1098ccfed362465b534400c8a93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=7191415$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2714342$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nolte, Hendrik</creatorcontrib><creatorcontrib>Gjedde, Susanne B.</creatorcontrib><creatorcontrib>Lindegaard-Madsen, Ebbe</creatorcontrib><creatorcontrib>Bergh, Jonas</creatorcontrib><creatorcontrib>Blomquist, Erik</creatorcontrib><creatorcontrib>Mouridsen, Henning T.</creatorcontrib><title>Phase II study of tauromustine in disseminated malignant melanoma</title><title>European journal of cancer & clinical oncology</title><addtitle>Eur J Cancer Clin Oncol</addtitle><description>Forty-seven patients with metastatic malignant melanoma took part in a phase II trial of tauromustine (TCNU), a new chlorethylnitrosourea based on the endogenous amino acid taurine. TCNU was given orally at a dosage of
130 mg/m
2
every fifth week. No patient had previously received cytotoxic therapy. Among
37 evaluable patients,
26 patients experienced progressive disease including seven patients with early death, five showed no change, and six partial responses, yielding an objective response rate of
16%. Responses were limited to subcutaneous, lymph node, bone and lung metastases. Median time to progression was
26 weeks for responders. The treatment schedule was well tolerated with a median dose of
88% of the predicted dose given during all cycles. Dose-limiting toxicity was thrombocytopenia. It appears that TCNU is active in disseminated malignant melanoma with a response rate similar to other nitrosoureas.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Chemotherapy</subject><subject>Drug Evaluation</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Melanoma - drug therapy</subject><subject>Melanoma - secondary</subject><subject>Middle Aged</subject><subject>Nitrosourea Compounds - adverse effects</subject><subject>Nitrosourea Compounds - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Taurine - adverse effects</subject><subject>Taurine - analogs & derivatives</subject><subject>Taurine - therapeutic use</subject><issn>0277-5379</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1989</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE9LxDAQxXNQ1nX1GyjkIKKHatImTXIRlsU_Cwt60HPIJlONNK0mrbDf3q5b9uhpYOa9x5sfQmeU3FBCy1uSC5HxQqgrqa4VyQnNyAGa7tdH6DilT0JyyXgxQZNcUFawfIrmLx8mAV4ucep6t8FthTvTxzb0qfMNYN9g51OC4BvTgcPB1P69MU2HA9SmaYM5QYeVqROcjnOG3h7uXxdP2er5cbmYrzLLqOgyUXHBgYFYK2FL4Ew6xvLSCe6cNRUwK5m0lChpbQWuKHNW8jUvGCPESqOKGbrc5X7F9ruH1Ongk4V6aAFtnzTljCoyvDVDbCe0sU0pQqW_og8mbjQlektLb7HoLRYtlf6jpclgOx_z-3UAtzeNqIb7xXg3yZq6iqaxPu1lgirKKB9kdzsZDCx-PESdrIfGgvMRbKdd6__v8Qs2X4dn</recordid><startdate>19890401</startdate><enddate>19890401</enddate><creator>Nolte, Hendrik</creator><creator>Gjedde, Susanne B.</creator><creator>Lindegaard-Madsen, Ebbe</creator><creator>Bergh, Jonas</creator><creator>Blomquist, Erik</creator><creator>Mouridsen, Henning T.</creator><general>Elsevier Ltd</general><general>Pergamon Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>19890401</creationdate><title>Phase II study of tauromustine in disseminated malignant melanoma</title><author>Nolte, Hendrik ; Gjedde, Susanne B. ; Lindegaard-Madsen, Ebbe ; Bergh, Jonas ; Blomquist, Erik ; Mouridsen, Henning T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c417t-7f575e4e7b97c6e548d4426d75ddcafe4c848c1098ccfed362465b534400c8a93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1989</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Chemotherapy</topic><topic>Drug Evaluation</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Melanoma - drug therapy</topic><topic>Melanoma - secondary</topic><topic>Middle Aged</topic><topic>Nitrosourea Compounds - adverse effects</topic><topic>Nitrosourea Compounds - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Taurine - adverse effects</topic><topic>Taurine - analogs & derivatives</topic><topic>Taurine - therapeutic use</topic><toplevel>online_resources</toplevel><creatorcontrib>Nolte, Hendrik</creatorcontrib><creatorcontrib>Gjedde, Susanne B.</creatorcontrib><creatorcontrib>Lindegaard-Madsen, Ebbe</creatorcontrib><creatorcontrib>Bergh, Jonas</creatorcontrib><creatorcontrib>Blomquist, Erik</creatorcontrib><creatorcontrib>Mouridsen, Henning T.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>European journal of cancer & clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nolte, Hendrik</au><au>Gjedde, Susanne B.</au><au>Lindegaard-Madsen, Ebbe</au><au>Bergh, Jonas</au><au>Blomquist, Erik</au><au>Mouridsen, Henning T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phase II study of tauromustine in disseminated malignant melanoma</atitle><jtitle>European journal of cancer & clinical oncology</jtitle><addtitle>Eur J Cancer Clin Oncol</addtitle><date>1989-04-01</date><risdate>1989</risdate><volume>25</volume><issue>4</issue><spage>655</spage><epage>657</epage><pages>655-657</pages><issn>0277-5379</issn><coden>EJCODS</coden><abstract>Forty-seven patients with metastatic malignant melanoma took part in a phase II trial of tauromustine (TCNU), a new chlorethylnitrosourea based on the endogenous amino acid taurine. TCNU was given orally at a dosage of
130 mg/m
2
every fifth week. No patient had previously received cytotoxic therapy. Among
37 evaluable patients,
26 patients experienced progressive disease including seven patients with early death, five showed no change, and six partial responses, yielding an objective response rate of
16%. Responses were limited to subcutaneous, lymph node, bone and lung metastases. Median time to progression was
26 weeks for responders. The treatment schedule was well tolerated with a median dose of
88% of the predicted dose given during all cycles. Dose-limiting toxicity was thrombocytopenia. It appears that TCNU is active in disseminated malignant melanoma with a response rate similar to other nitrosoureas.</abstract><cop>Oxford</cop><cop>New York, NY</cop><pub>Elsevier Ltd</pub><pmid>2714342</pmid><doi>10.1016/0277-5379(89)90201-0</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0277-5379 |
| ispartof | European journal of cancer & clinical oncology, 1989-04, Vol.25 (4), p.655-657 |
| issn | 0277-5379 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_15419014 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adolescent Adult Aged Antineoplastic agents Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Biological and medical sciences Chemotherapy Drug Evaluation Humans Medical sciences Melanoma - drug therapy Melanoma - secondary Middle Aged Nitrosourea Compounds - adverse effects Nitrosourea Compounds - therapeutic use Pharmacology. Drug treatments Taurine - adverse effects Taurine - analogs & derivatives Taurine - therapeutic use |
| title | Phase II study of tauromustine in disseminated malignant melanoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T04%3A21%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phase%20II%20study%20of%20tauromustine%20in%20disseminated%20malignant%20melanoma&rft.jtitle=European%20journal%20of%20cancer%20&%20clinical%20oncology&rft.au=Nolte,%20Hendrik&rft.date=1989-04-01&rft.volume=25&rft.issue=4&rft.spage=655&rft.epage=657&rft.pages=655-657&rft.issn=0277-5379&rft.coden=EJCODS&rft_id=info:doi/10.1016/0277-5379(89)90201-0&rft_dat=%3Cproquest_cross%3E15419014%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=15419014&rft_id=info:pmid/2714342&rft_els_id=0277537989902010&rfr_iscdi=true |